|
Volumn 64, Issue 25, 2014, Pages 2805-2806
|
Different potencies of angiotensin receptor blockers at suppressing adrenal β-arrestin1-dependent post-myocardial infarction hyperaldosteronism
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ALDOSTERONE;
ATRIAL NATRIURETIC FACTOR;
BETA ARRESTIN 1;
BRAIN NATRIURETIC PEPTIDE;
CANDESARTAN;
COLLAGEN TYPE 1;
IRBESARTAN;
VALSARTAN;
ANGIOTENSIN 1 RECEPTOR ANTAGONIST;
BENZIMIDAZOLE DERIVATIVE;
TETRAZOLE DERIVATIVE;
VALINE;
ANIMAL EXPERIMENT;
ANIMAL MODEL;
CLINICAL EFFECTIVENESS;
DRUG INDICATION;
DRUG POTENCY;
DRUG TREATMENT FAILURE;
HEART EJECTION FRACTION;
HEART FUNCTION;
HEART INFARCTION;
HEART MUSCLE FIBROSIS;
HEART PERFORMANCE;
HYPERALDOSTERONISM;
LETTER;
NONHUMAN;
POST MYOCARDIAL INFARCTION HYPERALDOSTERONISM;
RAT;
TREATMENT DURATION;
ANALOGS AND DERIVATIVES;
ANIMAL;
BLOOD;
COMPLICATION;
ALDOSTERONE;
ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS;
ANIMALS;
BENZIMIDAZOLES;
HYPERALDOSTERONISM;
MYOCARDIAL INFARCTION;
RATS;
TETRAZOLES;
VALINE;
|
EID: 84919673612
PISSN: 07351097
EISSN: 15583597
Source Type: Journal
DOI: 10.1016/j.jacc.2014.09.070 Document Type: Letter |
Times cited : (33)
|
References (5)
|